Therapy for diffuse large B-cell lymphoma: getting personal

被引：6

作者：

Cheson, Bruce D. ^{[1
]}

机构：

[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA

来源：

LANCET | 2013年 / 381卷 / 9880期

关键词：

CHEMOTHERAPY PLUS RITUXIMAB; STANDARD REGIMEN CHOP; ELDERLY-PATIENTS; TRIAL;

D O I：

10.1016/S0140-6736(13)60849-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1793 / 1794

页数：2

共 21 条

[1] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[2]

Benito JM, 2012, BLOOD, V120

[3] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[4]

Cunningham D, 2013, LANCET

[5] The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study [J].

Davids, Matthew S. ;

Roberts, Andrew W. ;

Anderson, Mary Ann ;

Pagel, John M. ;

Kahl, Brad S. ;

Gerecitano, John F. ;

Darden, David E. ;

Nolan, Cathy E. ;

Gressick, Lori A. ;

Yang, Jianning ;

Chyla, Brenda J. ;

Busman, Todd A. ;

Graham, Alison M. ;

Cerri, Elisa ;

Enschede, Sari H. ;

Humerickhouse, Rod A. ;

Seymour, John F. .

BLOOD, 2012, 120 (21)

[6]

Delarue R., 2013, Lancet Oncol

[7] COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].

FISHER, RI ;

GAYNOR, ER ;

DAHLBERG, S ;

OKEN, MM ;

GROGAN, TM ;

MIZE, EM ;

GLICK, JH ;

COLTMAN, CA ;

MILLER, TP .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006

[8]

Flinn WI HM, 2012, BLOOD, V120, P3663

[9] COMPARISON OF A 2ND-GENERATION COMBINATION CHEMOTHERAPEUTIC REGIMEN (M-BACOD) WITH A STANDARD REGIMEN (CHOP) FOR ADVANCED DIFFUSE NON-HODGKINS-LYMPHOMA [J].

GORDON, LI ;

HARRINGTON, D ;

ANDERSEN, J ;

COLGAN, J ;

GLICK, J ;

NEIMAN, R ;

MANN, R ;

RESNICK, GD ;

BARCOS, M ;

GOTTLIEB, A ;

OCONNELL, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (19) :1342-1349

[10] Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma [J].

Habermann, Thomas M. ;

Weller, Edie A. ;

Morrison, Vicki A. ;

Gascoyne, Randy D. ;

Cassileth, Peter A. ;

Cohn, Jeffrey B. ;

Dakhil, Shaker R. ;

Woda, Bruce ;

Fisher, Richard I. ;

Peterson, Bruce A. ;

Horning, Sandra J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3121-3127

← 1 2 3 →